Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

NASDAQ Market News

NEXT STORY
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PREV STORY
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with ...

author_avatar
NASDAQ Market News

TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

Novan Reports First Quarter 2017 Financial Results

MORRISVILLE, N.C., May 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) ...

author_avatar
NASDAQ Market News